Top Back to top

Outcomes of HLA-mismatched HSCT in patients with PID following in vitro T-cell depletion with CD3+TCRαβ/CD19 depleted PBSC or in vivo T-cell depleted HSCT with post-transplant cyclophosphamide

Inborn Errors Working Party (IEWP)
Study number:
Short title:
TCR αβ or PTCY mismatched HSCT in PID
Study status:
Data collection
Deadline for data collection:
Study design:
Retrospective study with additional data collection
Primary objective:
To compare overall and event free survival between the two groups. Events defined as graft failure, disease recurrence, severe chronic GVHD and severe autoimmunity or death
Key inclusion criteria:
Diagnosis: Primary Immunodeficiency/Autoimmune/Autoinflammatory disorders
Type of HSCT: first HSCT with either CD3+TCR αβ/CD19 depletion in vitro or with post-transplant cyclophosphamide in vivo
Donors: mismatched donors, either haploidentical MMFD or ≤9/10 MMUD, BM and PBSC
Date of first date of HSCT: 1.1.2010-31.12.2018

If you wish to participate in this study and did not receive an invitation please contact:
Principal investigator:
Mary Slatter & Michael Albert
Principal investigator email:
EBMT Study coordinator:
Sheree Hazelaar
Study coordinator email: